太极集团 沪股通 融押最新大宗交易 (2024-05-07) 官网 (重庆 600129.sh) | 19.08 | 4.30 | 1.03 | 1.05% | 上市时间1997-11-18股价28.57元 (1.78% , 2.44亿元) 市值159.10亿元流通市值159.10亿元股东人数4.91万人均自由流通市值20.90万元总股本5.57亿上市至今年化投资收益率6.00%陆股通持仓占流通A股比例1.31%融资融券余额占流通市值比例2.57%质押股数与前十大股东持股之比18.68%实际控制人国务院国有资产监督管理委员会 (国有) | ||||
| 所属三级行业中药 (申万) | 市盈率 | 26.37 | 市净率 | 2.48 | 市销率 | 2.46 | 股息率 | 2.29% | 申万2021版:医药生物中药中药国证:医药卫生制药中药 |
| 所属指数指数纳入纳出 |
| ||||||||
| 备注 (4): | 双击编辑备注 |
太极集团(600129) - 经营数据
最后更新于：2024-03-31
| 项目名称 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|
| 分行业 | |||
| 主营业务收入 (万元) | 416,325.31 | 1,549,812.00 | 1,206,109.00 |
| 医药工业 (万元) | 269,332.36 | 1,038,805.90 | 838,122.00 |
| 消化系统 (万元) | 68,219.13 | 269,194.00 | |
| 抗感染 (万元) | 39,749.10 | 149,102.00 | |
| 呼吸系统 (万元) | 100,505.17 | 189,925.00 | |
| 神经系统 (万元) | 15,758.51 | 63,330.00 | |
| 心脑血管 (万元) | 15,700.80 | 58,235.00 | |
| 抗肿瘤 (万元) | 8,098.53 | 21,042.00 | |
| 大健康产品 (万元) | 18,763.54 | 59,273.00 | |
| 医药商业 (万元) | 191,066.10 | 772,558.71 | 665,854.00 |
| 服务业及其他 (万元) | 47.57 | 5,223.96 | 4,664.00 |
| 分部间抵销 (万元) | 81,318.28 | 368,444.66 | 302,531.00 |
| 中药材资源 (万元) | 24,608.72 | 101,668.09 | |
| 大健康 (万元) | 12,588.84 | ||
| 主营业务成本 (万元) | 222,030.54 | 798,159.84 | 616,662.00 |
| 医药工业 (万元) | 94,544.60 | 366,323.02 | 297,901.00 |
| 消化系统 (万元) | 27,725.32 | 102,148.00 | |
| 抗感染 (万元) | 15,180.10 | 39,924.00 | |
| 呼吸系统 (万元) | 32,032.95 | 73,946.00 | |
| 神经系统 (万元) | 3,022.36 | 10,434.00 | |
| 心脑血管 (万元) | 3,473.73 | 13,171.00 | |
| 抗肿瘤 (万元) | 1,371.35 | 3,538.00 | |
| 大健康产品 (万元) | 8,855.91 | 28,117.00 | |
| 医药商业 (万元) | 174,593.68 | 698,411.62 | 608,946.00 |
| 服务业及其他 (万元) | 26.04 | 4,378.66 | 4,092.00 |
| 分部间抵销 (万元) | 82,068.36 | 364,586.09 | 294,277.00 |
| 中药材资源 (万元) | 22,934.05 | 93,632.63 | |
| 大健康 (万元) | 12,000.53 | ||
| 毛利率 | 46.67% | 48.87% | |
| 医药工业 | 64.90% | 64.74% | 64.46% |
| 消化系统 | 59.36% | 62.05% | |
| 抗感染 | 61.81% | 73.22% | |
| 呼吸系统 | 68.13% | 61.07% | |
| 神经系统 | 80.82% | 83.52% | |
| 心脑血管 | 77.88% | 77.38% | |
| 抗肿瘤 | 83.07% | 83.19% | |
| 大健康产品 | 52.80% | 52.56% | |
| 医药商业 | 8.62% | 9.60% | 8.55% |
| 服务业及其他 | 45.26% | 16.18% | 12.26% |
| 中药材资源 | 6.81% | 7.90% | |
| 大健康 | 4.67% | ||
| 分地区 | |||
| 主营业务收入 (万元) | 416,325.31 | 1,549,812.00 | 1,206,109.00 |
| 东北 (万元) | 6,833.95 | 299,912.56 | 25,288.00 |
| 华北 (万元) | 30,737.36 | 138,980.88 | 97,250.00 |
| 华东 (万元) | 95,085.89 | 31,840.83 | 222,189.00 |
| 华中 (万元) | 23,641.21 | 72,326.90 | 58,274.00 |
| 华南 (万元) | 32,097.34 | 131,243.90 | 101,076.00 |
| 西北 (万元) | 10,019.44 | 47,221.09 | 36,577.00 |
| 西南 (万元) | 217,690.55 | 827,412.56 | 664,952.00 |
| 境外 (万元) | 219.57 | 873.28 | 503.00 |
| 主营业务成本 (万元) | 222,030.54 | 798,159.84 | 616,662.00 |
| 东北 (万元) | 2,960.97 | 10,889.56 | 8,191.00 |
| 华北 (万元) | 11,672.83 | 42,903.40 | 27,765.00 |
| 华东 (万元) | 41,381.86 | 123,953.86 | 84,276.00 |
| 华中 (万元) | 11,702.33 | 28,778.87 | 23,209.00 |
| 华南 (万元) | 14,410.04 | 50,135.17 | 38,520.00 |
| 西北 (万元) | 4,382.78 | 18,935.66 | 14,333.00 |
| 西南 (万元) | 135,369.86 | 522,008.62 | 420,003.00 |
| 境外 (万元) | 149.87 | 554.70 | 365.00 |
| 毛利率 | 46.67% | 48.50% | 48.87% |
| 东北 | 56.67% | 65.80% | 67.61% |
| 华北 | 62.02% | 69.13% | 71.45% |
| 华东 | 56.48% | 58.67% | 62.07% |
| 华中 | 50.50% | 60.21% | 60.17% |
| 华南 | 55.11% | 61.80% | 61.89% |
| 西北 | 56.26% | 59.90% | 60.81% |
| 西南 | 37.82% | 36.91% | 36.84% |
| 境外 | 31.74% | 36.48% | 27.44% |
